GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Captor Therapeutics SA (WAR:CTX) » Definitions » EV-to-FCF

Captor Therapeutics (WAR:CTX) EV-to-FCF : -5.09 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Captor Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Captor Therapeutics's Enterprise Value is zł281.15 Mil. Captor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was zł-55.21 Mil. Therefore, Captor Therapeutics's EV-to-FCF for today is -5.09.

The historical rank and industry rank for Captor Therapeutics's EV-to-FCF or its related term are showing as below:

WAR:CTX' s EV-to-FCF Range Over the Past 10 Years
Min: -62.37   Med: -19.15   Max: -5.09
Current: -5.09

During the past 7 years, the highest EV-to-FCF of Captor Therapeutics was -5.09. The lowest was -62.37. And the median was -19.15.

WAR:CTX's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs WAR:CTX: -5.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Captor Therapeutics's stock price is zł76.00. Captor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was zł-15.190. Therefore, Captor Therapeutics's PE Ratio for today is At Loss.


Captor Therapeutics EV-to-FCF Historical Data

The historical data trend for Captor Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Captor Therapeutics EV-to-FCF Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -18.83 -24.45 -7.03

Captor Therapeutics Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.45 -22.45 -13.62 -10.44 -7.03

Competitive Comparison of Captor Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Captor Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Captor Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's EV-to-FCF falls into.



Captor Therapeutics EV-to-FCF Calculation

Captor Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=281.148/-55.209
=-5.09

Captor Therapeutics's current Enterprise Value is zł281.15 Mil.
Captor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-55.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Captor Therapeutics  (WAR:CTX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Captor Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=76.00/-15.190
=At Loss

Captor Therapeutics's share price for today is zł76.00.
Captor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-15.190.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Captor Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Captor Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Captor Therapeutics (WAR:CTX) Business Description

Traded in Other Exchanges
Address
ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Captor Therapeutics (WAR:CTX) Headlines

No Headlines